Agreements

Date: 2017-09-05

Type of information: Exercise of an option agreement

Compound: new medicines for the treatment of idiopathic pulmonary fibrosis

Company: Boehringer Ingelheim (Germany) Inventiva (France)

Therapeutic area: Lung diseases - Respiratory diseases - Rare diseases - Fibrotic diseases

Type agreement: research - R&D - licensing

Action mechanism:

Disease: idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases

Details:

• On May 31, 2016, Boehringer Ingelheim and Inventiva announced a new multi-year research and drug discovery collaboration and licensing agreement. Under the terms of the agreement, the Inventiva and Boehringer Ingelheim research teams will jointly validate a new therapeutic concept with the aim of discovering new medicines for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. The partnership will combine Inventiva’s deep knowhow and proprietary technologies in the field of transcriptional regulation and fibrosis with Boehringer Ingelheim’s capabilities in drug discovery and clinical development of new therapeutic agents. Boehringer Ingelheim has already developed nintedanib (Ofev®), a small molecule tyrosine kinase inhibitor, approved and marketed globally for the treatment of IPF in adults. The German group will be responsible for clinical development and commercialization of potential drug candidates from the collaboration.

Financial terms:

Inventiva will receive an upfront payment and is eligible to receive research funding, potential research, development, regulatory and commercial milestone payments of up to €170 million and tiered royalties on net sales of the products resulting from the partnership. Full financial details remain undisclosed.

Latest news:

• On September 5, 2017, Inventiva announced the exercise of an option by Boehringer Ingelheim advancing the collaboration, which began in May 2016. The joint research team has validated a new fibrosis target and data generated in the program supports its therapeutic potential in fibrotic conditions and idiopathic pulmonary fibrosis has been selected as the first indication to be investigated. Boehringer Ingelheim’s execution of this option triggers a milestone payment to Inventiva of €2.5m.